These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 21683932)

  • 1. Clinical amyloid imaging in Alzheimer's disease.
    Herholz K; Ebmeier K
    Lancet Neurol; 2011 Jul; 10(7):667-70. PubMed ID: 21683932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long night's journey into the day: amyloid-β imaging in Alzheimer's disease.
    Villemagne VL; Rowe CC
    J Alzheimers Dis; 2013; 33 Suppl 1():S349-59. PubMed ID: 22710919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Alzheimer-disease neuroimaging-biomarkers using mouse models with amyloid-precursor protein-transgene expression.
    Teipel SJ; Buchert R; Thome J; Hampel H; Pahnke J
    Prog Neurobiol; 2011 Dec; 95(4):547-56. PubMed ID: 21601614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular imaging of dementia.
    Mori T; Maeda J; Shimada H; Higuchi M; Shinotoh H; Ueno S; Suhara T
    Psychogeriatrics; 2012 Jun; 12(2):106-14. PubMed ID: 22712644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo detection of amyloid β deposition using ¹⁹F magnetic resonance imaging with a ¹⁹F-containing curcumin derivative in a mouse model of Alzheimer's disease.
    Yanagisawa D; Amatsubo T; Morikawa S; Taguchi H; Urushitani M; Shirai N; Hirao K; Shiino A; Inubushi T; Tooyama I
    Neuroscience; 2011 Jun; 184():120-7. PubMed ID: 21497641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study.
    Barthel H; Gertz HJ; Dresel S; Peters O; Bartenstein P; Buerger K; Hiemeyer F; Wittemer-Rump SM; Seibyl J; Reininger C; Sabri O;
    Lancet Neurol; 2011 May; 10(5):424-35. PubMed ID: 21481640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.
    Okamura N; Yanai K
    IDrugs; 2010 Dec; 13(12):890-9. PubMed ID: 21154149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET imaging of amyloid in Alzheimer's disease.
    Nordberg A
    Lancet Neurol; 2004 Sep; 3(9):519-27. PubMed ID: 15324720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies.
    Rinne JO; Wong DF; Wolk DA; Leinonen V; Arnold SE; Buckley C; Smith A; McLain R; Sherwin PF; Farrar G; Kailajärvi M; Grachev ID
    Acta Neuropathol; 2012 Dec; 124(6):833-45. PubMed ID: 23053137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status of PET-imaging probes of β-amyloid plaques.
    Koo J; Byun Y
    Arch Pharm Res; 2013 Oct; 36(10):1178-84. PubMed ID: 23812777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.
    Fleisher AS; Chen K; Liu X; Roontiva A; Thiyyagura P; Ayutyanont N; Joshi AD; Clark CM; Mintun MA; Pontecorvo MJ; Doraiswamy PM; Johnson KA; Skovronsky DM; Reiman EM
    Arch Neurol; 2011 Nov; 68(11):1404-11. PubMed ID: 21747008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Amyloid-plaque imaging of the brain using PET].
    Ossenkoppele R; Tolboom N; Pijnenburg YA; Lammertsma AA; Scheltens P; van Berckel BN
    Ned Tijdschr Geneeskd; 2011; 155():A2981. PubMed ID: 21586182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging brain amyloid deposition using grating-based differential phase contrast tomography.
    Pinzer BR; Cacquevel M; Modregger P; McDonald SA; Bensadoun JC; Thuering T; Aebischer P; Stampanoni M
    Neuroimage; 2012 Jul; 61(4):1336-46. PubMed ID: 22450300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic accuracy of (18)F amyloid PET tracers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.
    Morris E; Chalkidou A; Hammers A; Peacock J; Summers J; Keevil S
    Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):374-385. PubMed ID: 26613792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Florbetaben to trace amyloid-β in the Alzheimer brain by means of PET.
    Barthel H; Sabri O
    J Alzheimers Dis; 2011; 26 Suppl 3():117-21. PubMed ID: 21971456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloid-plaque imaging in early and differential diagnosis of dementia.
    Drzezga A
    Ann Nucl Med; 2010 Feb; 24(2):55-66. PubMed ID: 20082230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinically different stages of Alzheimer's disease associated by amyloid deposition with [11C]-PIB PET imaging.
    Hatashita S; Yamasaki H
    J Alzheimers Dis; 2010; 21(3):995-1003. PubMed ID: 20693641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDG-PET and amyloid-PET imaging: the diverging paths.
    Perani D
    Curr Opin Neurol; 2014 Aug; 27(4):405-13. PubMed ID: 24927239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-florbetapir PET in patients with frontotemporal dementia and Alzheimer disease.
    Kobylecki C; Langheinrich T; Hinz R; Vardy ER; Brown G; Martino ME; Haense C; Richardson AM; Gerhard A; Anton-Rodriguez JM; Snowden JS; Neary D; Pontecorvo MJ; Herholz K
    J Nucl Med; 2015 Mar; 56(3):386-91. PubMed ID: 25655625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.